Tarsus Pharmaceuticals Analyst Ratings
Tarsus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 173.48% | Guggenheim | → $46 | Reiterates | Buy → Buy |
| 08/11/2023 | 149.7% | HC Wainwright & Co. | $50 → $42 | Maintains | Buy |
| 07/26/2023 | 197.27% | HC Wainwright & Co. | $44 → $50 | Maintains | Buy |
| 07/18/2023 | 161.59% | William Blair | → $44 | Initiates Coverage On | → Outperform |
| 06/26/2023 | 161.59% | HC Wainwright & Co. | $40 → $44 | Maintains | Buy |
| 06/16/2023 | 149.7% | Guggenheim | $40 → $42 | Maintains | Buy |
| 05/18/2023 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 05/08/2023 | 155.65% | Oppenheimer | → $43 | Reiterates | → Outperform |
| 03/15/2023 | 137.81% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
| 08/01/2022 | 137.81% | Barclays | → $40 | Initiates Coverage On | → Overweight |
| 12/21/2021 | 137.81% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 11/23/2021 | 226.99% | Oppenheimer | → $55 | Initiates Coverage On | → Outperform |
| 10/08/2021 | 286.44% | Raymond James | $50 → $65 | Maintains | Strong Buy |
| 06/29/2021 | 197.27% | Raymond James | $39 → $50 | Maintains | Strong Buy |
| 11/10/2020 | 149.7% | Ladenburg Thalmann | → $42 | Initiates Coverage On | → Buy |
| 11/10/2020 | 96.2% | B of A Securities | → $33 | Initiates Coverage On | → Buy |
| 11/10/2020 | 108.09% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 11/10/2020 | 131.87% | Raymond James | → $39 | Initiates Coverage On | → Strong Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月14日 | 173.48% | 古根海姆 | →$46 | 重申 | 购买→购买 |
| 2023年08月11日 | 149.7% | HC Wainwright公司 | $50→$42 | 维护 | 买 |
| 07/26/2023 | 197.27% | HC Wainwright公司 | $44→$50 | 维护 | 买 |
| 07/18/2023 | 161.59% | 威廉·布莱尔 | →$44 | 开始承保 | →跑赢大盘 |
| 2023/06/26 | 161.59% | HC Wainwright公司 | $40→$44 | 维护 | 买 |
| 06/16/2023 | 149.7% | 古根海姆 | $40→$42 | 维护 | 买 |
| 2023年05月18日 | - | 古根海姆 | 开始承保 | →购买 | |
| 05/08/2023 | 155.65% | 奥本海默 | →$43 | 重申 | →跑赢大盘 |
| 03/15/2023 | 137.81% | HC Wainwright公司 | →$40 | 重申 | →购买 |
| 08/01/2022 | 137.81% | 巴克莱 | →$40 | 开始承保 | →超重 |
| 2021/12/21 | 137.81% | HC Wainwright公司 | →$40 | 开始承保 | →购买 |
| 2021年11月23日 | 226.99% | 奥本海默 | →$55 | 开始承保 | →跑赢大盘 |
| 10/08/2021 | 286.44% | 雷蒙德·詹姆斯 | $50→$65 | 维护 | 强势购买 |
| 2021/06/29 | 197.27% | 雷蒙德·詹姆斯 | $39→$50 | 维护 | 强势购买 |
| 11/10/2020 | 149.7% | 拉登堡·塔尔曼 | →$42 | 开始承保 | →购买 |
| 11/10/2020 | 96.2% | B of A证券 | →$33 | 开始承保 | →购买 |
| 11/10/2020 | 108.09% | 杰富瑞 | →$35 | 开始承保 | →购买 |
| 11/10/2020 | 131.87% | 雷蒙德·詹姆斯 | →$39 | 开始承保 | →强势购买 |
What is the target price for Tarsus Pharmaceuticals (TARS)?
塔尔苏斯制药公司(Tarsus PharmPharmticals)的目标价是多少？
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on August 14, 2023. The analyst firm set a price target for $46.00 expecting TARS to rise to within 12 months (a possible 173.48% upside). 9 analyst firms have reported ratings in the last year.
古根海姆于2023年8月14日报道了塔尔苏斯制药公司(纳斯达克代码：TARS)的最新目标价。这家分析公司将目标价定为46美元，预计TARS将在12个月内升至(可能上涨173.48%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?
塔尔苏斯制药公司(TARS)最近的分析师评级是多少？
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ: TARS) was provided by Guggenheim, and Tarsus Pharmaceuticals reiterated their buy rating.
古根海姆提供了塔尔苏斯制药公司(纳斯达克代码：TARS)的最新分析师评级，塔尔苏斯制药公司重申了其买入评级。
When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?
塔尔苏斯制药公司(TARS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与塔尔苏斯制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Tarsus制药的上一次评级是在2023年8月14日提交的，所以你应该预计下一次评级将在2024年8月14日左右的某个时候公布。
Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?
分析师对Tarsus PharmPharmticals(TARS)的评级正确吗？
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a reiterated with a price target of $0.00 to $46.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $16.82, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但塔尔苏制药(TARS)的最新评级被重申，目标价在0.00美元至46.00美元之间。塔尔苏斯制药公司(Tarsus PharmPharmticals)目前的交易价格为16.82美元，在分析师的预测范围内。